verified SJR 0,632 · Q2 • database Scopus / SJR & Web of Science & DOAJ indexed

Hong Kong · AME Publishing Company

workspace_premium Q2 — Medicine (miscellaneous) lock Subscription · DOAJ

Chinese Clinical Oncology

Chinese Clinical Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 40. It has an SJR impact factor of 0,632 and it has a best quartile of Q2. It has an SJR impact factor of 0,632.

ISSN: 2304-3865

Publisher: AME Publishing Company

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science verifiedDOAJ

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,632 Q2

H-index 40

Acceptance rate pie_chart

36%

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science DOAJ

SJR Impact

0,632

H-index

Docs (year)

Docs 3y

186

Total refs

4600

Cites 3y

311

Citable 3y

142

Cites/Doc 2y

1.63

Ref/Doc

50.55

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Cancer immunotherapy - the end of the beginning

Who, how and what of pathology of soft tissue sarcoma

Dan Sargent, CCO Associate Editor and Mayo biostatistician and clinical trialist, dies unexpectedly at 46

Current status and evolving treatment for primary liver cancers

Current management of primary central nervous system lymphoma

Cost-comparativeness of proton versus photon therapy

Contemporary management of ductal carcinoma in situ and lobular carcinoma in situ

Comparison of short-term outcomes between laparoscopic-assisted and open complete mesocolic excision (CME) for the treatment of transverse colon cancer

Chromodomain-helicase-DNA-binding protein 4: a novel therapeutic target in liver cancer stem cells

Chimeric antigen receptor (CAR) T and other T cell strategies for pancreas adenocarcinoma

Chemotherapy principles of managing stage IV breast cancer in the United States

Challenges in imaging assessment following liver stereotactic body radiotherapy: pitfalls to avoid in clinical practice

SHOW MORE ARTICLES

CD30+ T-cell lymphoproliferative disorders

A view of the epidemiologic landscape: how population-based studies can lend novel insights regarding the pathophysiology of glioblastoma

Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cance

Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017

Beginnings of a "gene cloud" definition in hepatocellular carcinoma

An update on radiation therapy for brain metastases

An overview of modern proton therapy

Allogeneic hematopoietic stem cell transplantation in advanced stage mycosis fungoides and Sezary syndrome: a concise review

Advances in treatment and care in metastatic breast cancer (MBC): are there MBC patients who are curable?

Advances in surgical approaches in glioblastoma (GBM)

Advances in external beam stereotactic body radiotherapy: principle concerns in implementing a liver radiation program

Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma

FAQs

Chinese Clinical Oncology has an SJR of 0,632 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Chinese Clinical Oncology is 36%.

Chinese Clinical Oncology

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Chinese Clinical Oncology?

What is the APC / publication cost?

What is the acceptance rate?